Pharmaids Pharmaceuticals Ltd Falls to 52-Week Low of Rs.34

Stock Price Movement and Market Context

On 19 Feb 2026, Pharmaids Pharmaceuticals Ltd’s share price reached Rs.34, the lowest in the past year. Despite outperforming its sector by 1.45% today and showing a modest gain after two consecutive days of decline, the stock remains substantially below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This persistent weakness contrasts with the broader market, where the Sensex, although experiencing a sharp reversal and closing 1.48% lower at 82,498.14, remains only 4.44% below its 52-week high of 86,159.02.

Pharmaids’ one-year performance starkly contrasts with the Sensex’s 8.64% gain, as the stock has declined by 43.46% over the same period. This underperformance extends beyond the last year, with the company lagging behind the BSE500 index across one-year, three-year, and three-month timeframes.

Financial Performance and Fundamental Assessment

The company’s financial metrics reveal ongoing challenges. Pharmaids Pharmaceuticals Ltd has reported operating losses, contributing to a weak long-term fundamental profile. Over the past five years, operating profit has declined at an annualised rate of 1.81%, indicating subdued growth prospects. The firm’s ability to service debt is also under pressure, with an average EBIT to interest coverage ratio of -6.18, signalling difficulties in meeting interest obligations from earnings before interest and tax.

Profitability concerns are further underscored by a negative EBITDA, which places the stock in a risky valuation category relative to its historical averages. Over the last year, profits have fallen by 34%, compounding the stock’s negative return of 43.46%. This combination of declining profitability and share price depreciation has contributed to the stock’s downgrade in rating from Sell to Strong Sell, as reflected in its current Mojo Grade of 17.0.

Quarterly Results and Sales Growth

Despite the overall negative trend, Pharmaids Pharmaceuticals Ltd reported some positive quarterly results in December 2025. Net sales for the quarter stood at Rs.5.43 crores, representing a robust growth of 42.2% compared to the previous four-quarter average. However, the company’s PBDIT remained negative at Rs.-2.50 crores, albeit the highest recorded in recent quarters. The operating profit to net sales ratio also improved to its highest level at -46.04%, indicating some operational leverage despite ongoing losses.

Shareholding Pattern and Market Capitalisation

The majority of Pharmaids Pharmaceuticals Ltd’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company’s market capitalisation grade is rated at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector. This classification often entails higher volatility and sensitivity to sector-specific developments.

Sector and Industry Comparison

Operating within the Pharmaceuticals & Biotechnology sector, Pharmaids Pharmaceuticals Ltd’s performance contrasts with broader sector trends. While the sector has experienced fluctuations, the company’s sustained decline and weak fundamentals have resulted in a significant divergence from sector averages. The stock’s current Mojo Grade of Strong Sell, upgraded from Sell on 28 May 2025, highlights the deteriorated outlook relative to peers.

Technical Indicators and Trend Analysis

From a technical perspective, Pharmaids Pharmaceuticals Ltd is trading below all major moving averages, signalling a sustained bearish trend. The stock’s recent gain after two days of decline may indicate a short-term pause in selling pressure, but the overall trend remains downward. This technical weakness is compounded by the stock’s underperformance relative to the Sensex and its sector peers.

Summary of Key Metrics

To summarise, Pharmaids Pharmaceuticals Ltd’s stock has declined by 43.46% over the past year, with profits falling by 34%. The company’s operating profit has contracted at an annualised rate of 1.81% over five years, and its EBIT to interest coverage ratio is negative at -6.18. The stock’s Mojo Score of 17.0 and Strong Sell grade reflect these challenges, alongside its micro-cap status and majority non-institutional shareholding.

While the company has shown some improvement in quarterly sales and operating profit margins, these have not yet translated into positive earnings or a reversal of the long-term downtrend in share price.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today